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Abstract: Background: Antimicrobials have been widely used during the COVID-19 pandemic. This 
study aimed to analyze the impact of the COVID-19 pandemic on the antimicrobial consumption of 
66 hospitals in Catalonia. Methods: Adult antibacterial and antimycotic consumption was calcu-
lated as defined daily doses (DDD)/100 bed-days and DDD/100 discharges. Firstly, overall and ICU 
consumption in 2019 and 2020 were compared. Secondly, observed ICU 2020 consumptions were 
compared with non-COVID-19 2020 estimated consumptions (based on the trend from 2008–2019). 
Results: Overall, antibacterial consumption increased by 2.31% and 4.15% DDD/100 bed-days and 
DDD/100 discharges, respectively. Azithromycin (105.4% and 109.08% DDD/100 bed-days and 
DDD/100 discharges, respectively) and ceftriaxone (25.72% and 27.97% DDD/100 bed-days and 
DDD/100 discharges, respectively) mainly accounted for this finding. Likewise, antifungal con-
sumption increased by 10.25% DDD/100 bed-days and 12.22% DDD/100 discharges, mainly due to 
echinocandins or amphotericin B. ICU antibacterial and antimycotic consumption decreased by 
1.28% and 4.35% DDD/100 bed-days, respectively. On the contrary, antibacterial and antifungal use, 
expressed in DDD/100 discharges, increased by 23.42% and 19.58%. Azithromycin (275.09%), ceftri-
axone (55.11%), cefepime (106.35%), vancomycin (29.81%), linezolid (31.28%), amphotericin B 
(87.98%), and voriconazole (96.17%) use changed the most. Observed consumption of amphotericin 
B, azithromycin, caspofungin, ceftriaxone, vancomycin, and voriconazole were higher than esti-
mated values. Conclusions: The consumption indicators for most antimicrobials deviated from the 
expected trend pattern. A worrisome increase in antibacterial and antifungal consumption was ob-
served in ICUs in Catalonia. 
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1. Introduction 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the corona-
virus-disease 19 (COVID-19) [1]. This virus has caused the worst pandemic in the last 
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century, posing a global threat [1]. At the health level, this pandemic has placed an unsus-
tainable pressure on hospital systems, and especially on intensive care units (ICUs) [2,3]. 
The worldwide impact of the COVID-19 pandemic has been devastating, with more than 
177,866,160 cases and 3,857,974 deaths, as of 24 June 2021 [4]. 
COVID-19 is characterized by a first phase with typical viral symptoms, followed by 
an inflammatory phase [5]. While 80% of patients present a mild clinical course, 5–14.2% 
require ICU admission and 6.1–12.2% require mechanical ventilation [6,7]. 
Bacterial and fungal co-infections and secondary infections are common in viral in-
fections and are associated with increased morbidity and mortality [8]. In hospitalized 
patients infected with influenza, 23% present a bacterial co-infection, mainly due to Staph-
ylococcus aureus or Streptococcus pneumoniae [9]. In other viruses, this rate is 40% [10]. Based 
on these data, at the beginning of the COVID-19 pandemic, antibiotics were widely used. 
However, subsequent studies demonstrated that the bacterial infection rate was lower 
than expected, with an incidence of 5.9% in hospital wards and 8.1% in ICUs [2], most of 
them due to S. aureus and Haemophilus influenzae [8]. Despite this information, the preva-
lence of antibiotic prescriptions was 74.6–85.2% [8,11]. Since then, international guidelines 
have accordingly adapted their recommendations, reserving the use of antibiotics for crit-
ically ill patients, or when a high clinical suspicion of bacterial infection exists [12]. 
This overuse of antibiotics may worsen the other pandemic of our century—that of 
global bacterial resistance [2,8]. In this setting, antimicrobial stewardship teams are indis-
pensable to optimize antibiotic prescription and decrease the spread of multidrug-re-
sistant organisms [2,11]. A knowledge of local consumption patterns is essential to iden-
tify opportunities and implement antibiotic policies that optimize their prescription. In 
the case of COVID-19, this information is crucial to learn from possible errors and avoid 
antibiotic misuse, both in further waves and other viral pandemics, which seem inevita-
ble. 
Antimicrobial consumption during the COVID-19 pandemic has previously been de-
scribed [3,8,13–15]. However, most of these studies have been of single centers, with small 
sample sizes, and have not included the consumption indicator defined daily doses 
(DDD)/100 discharges or have not focused on the consumption in the ICU or the con-
sumption of antifungals. 
Catalonia, a Spanish region of 7.5 million inhabitants, developed the Catalan Infec-
tion Control Program (VINCat) 14 years ago. This program is a healthcare-associated in-
fection surveillance program, which includes several objectives such as the knowledge of 
the incidence of nosocomial infections, catheter-related infections, and surgical wound 
infections [16]. One of the goals of this program is to control the use of antimicrobials in 
hospitals in this region through the extension of the implantation of antimicrobial stew-
ardship programs (VINCat-PROA) in these centers, to later be extended to all areas of 
antimicrobial use. For that purpose, antimicrobial consumption is monitored every year. 
The objective of this study was to analyze the impact of the COVID-19 pandemic in 
the antimicrobial consumption of hospitals included in the VINCat-PROA program, with 
emphasis on the ICU. 
2. Results 
2.1. Evolution of COVID-19 Pandemic in Catalonia during 2020 
The first COVID-19 case in Catalonia was diagnosed on 25 February 2020. Since then, 
a total of 356,724 positive cases were diagnosed in 2020, with a mean effective reproduc-
tion number of 0.8 and a mean 14 day incidence of 1006.79 cases per 100,000 inhabitants 
[17,18]. A total of 8723 deaths were notified, with 29,773 hospitalizations and 2426 ICU 
admissions [18]. 
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2.2. Evolution of Overall and ICU Bed-Days and Discharges 2008–2020 
The number of hospitals participating in the VINCat-PROA rose from 46 in 2008 to 
66 in 2020 throughout the study period. These figures represented 68.8% and 89.7% of all 
adult acute hospital beds in Catalonia at these two time points. The number of recorded 
bed-days increased from 2,991,053 in 2008 to 3,557,047 in 2020, whereas the number of 
discharges increased from 497,306 in 2008 to 595,103 in 2020 (Figure 1.) 
 
Figure 1. Evolution of overall and intensive care unit (ICU) bed-days and discharges 2008–2020. 
Between 2019 and 2020, the number of participating hospitals increased from 64 to 
66. The number of overall bed-days decreased by 0.05% (3,741,936 vs. 3,557,047 bed-days), 
and the number of discharges decreased by 0.07% (637,243 vs. 595,103 discharges). Re-
garding ICUs, the number of bed-days increased by 29.08% (194,011 vs. 250,425 bed-days) 
and the number of discharges increased by 3.24% (43,610 vs. 45,024 discharges). The hos-
pitals added in 2020 were two small hospitals. Between them, they accounted for 22.662 
bed-days and 5.365 overall discharges (0.6% and 0.9% of the total, respectively). With re-
spect to the ICU, they accounted for 775 bed-days and 115 discharges (0.3% and 0.2% of 
the total, respectively). 
The median number of overall and ICU days per patient in 2020 increased by 2.93% 
(5.8 vs. 5.97 days) and by 24.94% (4.45 vs. 5.56 days), respectively. 
2.3. Changes in Global Consumption of Anti-Infectives for Systemic Use 2019–2020 
The overall consumption of antibacterials in 2020 increased, compared to 2019, by 
2.31% for DDD/100 bed-days (69.38 vs. 70.99; p < 0.001) and by 4.15% for DDD/100 dis-
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Table 1. Changes in overall and intensive care unit (ICU) consumption of anti-infectives for systemic use, 2019–2020. 
 DDD/100 Bed-Days DDD/100 Discharges 
Service ATC classification 2019 2020 
Variation 
(%) 





J01 Antibacterials for systemic use 69.38 70.99 2.31 <0.001 407.41 424.30 4.15 <0.001 
J01C Penicillins 23.63 21.70 −8.18 <0.001 138.76 129.69 −6.53 <0.001 
 J01CR Combinations of penicillins. incl. 
beta-lactamase inhibitors 
18.26 16.80 −7.98 <0.001 107.23 100.44 −6.33 <0.001 
J01DBCDE Cephalosporins 14.10 15.19 7.78 <0.001 82.78 90.82 9.71 <0.001 
 J01DD Third-generation cephalosporins 7.56 9.51 25.72 <0.001 44.40 56.82 27.97 <0.001 
 J01DE Fourth-generation cephalosporins 0.64 0.65 2.05 0.03 3.75 3.89 3.87 <0.001 
J01DH Carbapenems 5.01 5.16 2.93 <0.001 29.41 30.82 4.77 <0.001 
J01DI Other cephalosporins and penems 0.29 0.37 29.00 <0.001 1.68 2.20 31.32 <0.001 
J01FA Macrolides 3.26 6.69 105.40 <0.001 19.13 40.00 109.08 <0.001 
J01G Aminoglycoside antibacterials 1.82 1.63 −10.72 <0.001 10.69 9.71 −9.12 <0.001 
J01M Quinolone antibacterials 8.48 7.20 −15.01 <0.001 49.77 43.06 −13.49 <0.001 
J01X Other antibacterials 8.89 9.39 5.72 <0.001 52.18 56.15 7.61 <0.001 
 J01XA Glycopeptide antibacterials 2.56 2.75 7.43 <0.001 15.01 16.42 9.36 <0.001 
 J01XB Polymyxins 0.39 0.34 −12.96 <0.001 2.28 2.02 −11.40 <0.001 
 J01XX Other antibacterials 3.70 4.01 8.45 <0.001 21.72 23.98 10.39 <0.001 
J02A Antimycotics for systemic use 3.11 3.43 10.25 <0.001 18.24 20.47 12.22 <0.001 
 J02AB Imidazole derivatives 0.00 0.00 −81.25 <0.001 0.03 0.01 −80.99 <0.001 
 J02AC Triazole derivatives 2.61 2.81 7.85 <0.001 15.31 16.81 9.78 <0.001 
 J02AX Other antimycotics for systemic use 0.39 0.44 14.62 <0.001 2.27 2.64 16.67 <0.001 
ICU 
J01 Antibacterials for systemic use 
114.2
3 
112.77 −1.28 <0.001 508.18 627.21 23.42 <0.001 
J01C Penicillins 32.92 27.40 −16.78 <0.001 146.46 152.38 4.04 <0.001 
 J01CR Combinations of penicillins. incl. 
beta-lactamase inhibitors 
23.24 18.74 −19.35 <0.001 103.37 104.23 0.84 0.21 
J01DBCDE Cephalosporins 17.26 18.20 5.46 <0.001 76.80 101.26 31.84 <0.001 
 J01DD Third-generation cephalosporins 12.11 13.78 13.82 <0.001 53.87 76.66 42.30 <0.001 
 J01DE Fourth-generation cephalosporins 1.20 1.98 65.04 <0.001 5.35 11.03 106.35 <0.001 
J01DH Carbapenems 14.66 14.02 −4.32 <0.001 65.20 77.99 19.62 <0.001 
J01DI Other cephalosporins and penems 0.87 1.19 36.09 <0.001 3.88 6.60 70.13 <0.001 
J01FA Macrolides 7.62 13.60 78.44 <0.001 33.90 75.62 123.09 <0.001 
J01G Aminoglycoside antibacterials 4.11 3.88 −5.64 <0.001 18.30 21.58 17.97 <0.001 
J01M Quinolone antibacterials 9.33 8.18 −12.39 <0.001 41.52 45.48 9.54 <0.001 
J01X Other antibacterials 19.34 19.67 1.69 0.01 86.04 109.38 27.13 <0.001 
 J01XA Glycopeptide antibacterials 5.41 5.65 4.49 <0.001 24.07 31.45 30.64 <0.001 
 J01XB Polymyxins 1.17 1.64 40.27 <0.001 5.20 9.11 75.36 <0.001 
 J01XX Other antibacterials 10.46 10.82 3.40 <0.001 46.55 60.18 29.28 <0.001 
J02A Antimycotics for systemic use 12.35 11.81 −4.35 <0.001 54.93 65.68 19.58 <0.001 
 J02AB Imidazole derivatives 0.00 0.00 - - 0.00 0.00 - - 
 J02AC Triazole derivatives 8.91 8.36 −6.17 <0.001 39.62 46.48 17.31 <0.001 
 J02AX Other antimycotics for systemic use 3.00 2.79 −6.96 <0.001 13.36 15.54 16.33 <0.001 
ICU: Intensive care unit; DDD: Defined daily doses; ATC: Anatomical therapeutic chemical. 
This increase is mainly due to an increase in the consumption of macrolides and 
third-generation cephalosporins. It has been observed both in the consumption, expressed 
in DDD/100 bed-days (105.40%, p < 0.001 and 25.72%; p < 0.001, respectively), and in the 
consumption, expressed in DDD/100 discharges (109.08%, p < 0.001 and 27.97%; p < 0.001, 
respectively). A statistically significant decrease in the consumption of penicillins, amino-
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glycosides, and quinolones was also observed. The consumption of antifungals also in-
creased significantly during 2020, both in DDD/100 bed-days (10.25%; 3.11 vs 3.43; p < 
0.001) and in DDD/100 discharges (12.22%; 18.24 vs. 20.47; p < 0.001). 
2.4. Changes in ICU Consumption of Anti-Infectives for Systemic Use 2019–2020 
The variation in consumption in 2020 compared to 2019 in ICUs showed important 
differences, depending on whether it was calculated in DDD/100 bed-days or in DDD/100 
discharges (Tables 1 and 2). 
Table 2. Changes in intensive care unit (ICU) consumption of major anti-infectives for systemic use 2019–2020. 
 ICU DDD/100 Bed-Days ICU  DDD/100 Discharges 
ATC Classification 2019 2020 Variation (%) p 2019 2020 Variation (%) p 
J02AA01 Amphotericin B 0.44 0.66 50.34 <0.001 1.95 3.67 87.98 <0.001 
J01GB06 Amikacin 2.12 2.22 4.91 0.02 9.43 12.37 31.16 <0.001 
J01CR02 Amoxicillin and 
beta-lactamase inhibitor 
12.94 9.13 −29.42 <0.001 57.58 50.81 −11.76 <0.001 
J02AX06 Anidulafungin 1.93 1.95 1.40 0.52 8.57 10.86 26.77 <0.001 
J01FA10 Azithromycin 2.77 8.32 200.01 <0.001 12.34 46.28 275.09 <0.001 
J02AX04 Caspofungin 0.38 0.45 20.13 <0.001 1.68 2.52 50.18 <0.001 
J01DE01 Cefepime 1.20 1.98 65.04 <0.001 5.35 11.03 106.35 <0.001 
J01DI02 Ceftaroline fosamil 0.43 0.31 −28.21 <0.001 1.91 1.71 −10.25 0.03 
J01DD02 Ceftazidime 2.28 2.20 −3.89 0.05 10.17 12.21 20.16 <0.001 
J01DD52 Ceftazidime and 
beta-lactamase inhibitor 
0.33 0.58 77.11 <0.001 1.46 3.23 121.47 <0.001 
J01DI54 Ceftolozane and 
beta-lactamase inhibitor  
0.44 0.88 98.22 <0.001 1.97 4.89 147.81 <0.001 
J01DD04 Ceftriaxone 6.61 8.19 24.07 <0.001 29.38 45.58 55.11 <0.001 
J01MA02 Ciprofloxacin 3.31 3.47 4.72 0.01 14.73 19.28 30.92 <0.001 
J01CF02 Cloxacillin 7.56 6.45 −14.69 <0.001 33.62 35.86 6.66 <0.001 
J01XB01 Colistin 1.17 1.64 40.27 <0.001 5.20 9.11 75.36 <0.001 
J01XA04 Dalbavancin 0.00 0.00 57.14 0.68 0.00 0.01 96.67 0.53 
J01XX09 Daptomycin 5.26 5.53 5.13 <0.001 23.42 30.78 31.44 <0.001 
J01DH03 Ertapenem 1.45 1.27 −12.83 <0.001 6.46 7.04 8.99 <0.001 
J02AC01 Fluconazole 7.19 6.17 −14.12 <0.001 31.98 34.34 7.37 <0.001 
J01DH51 Imipenem-cilas-
tatin 
1.02 0.70 −31.62 <0.001 4.54 3.89 −14.50 <0.001 
J02AC05 Isavuconazole 0.34 0.29 −14.33 <0.001 1.52 1.63 7.10 0.20 
J01XX08 Linezolid 4.81 5.06 5.01 <0.001 21.42 28.12 31.28 <0.001 
J01DH02 Meropenem 12.18 12.06 −1.02 0.24 54.19 67.06 23.75 <0.001 
J02AX05 Micafungin  0.70 0.39 −44.67 <0.001 3.10 2.14 −30.81 <0.001 
J01CR05 Piperacillin and 
beta-lactamase inhibitor 
10.29 9.61 −6.68 <0.001 45.79 53.43 16.68 <0.001 
J02AC04 Posaconazole 0.25 0.09 −63.53 <0.001 1.12 0.51 −54.39 <0.001 
J01XA01 Vancomycin 2.76 2.87 3.83 0.04 12.30 15.97 29.81 <0.001 
J02AC03 Voriconazole 1.12 1.76 56.92 <0.001 4.99 9.80 96.17 <0.001 
ICU: Intensive care unit; DDD: Defined daily doses; ATC: Anatomical therapeutic chemical. 
The consumption of antibacterials, expressed in DDD/100 bed-days, decreased by 
1.28% in 2020 (114.23 vs. 112.77; p < 0.001), mainly due to a decrease in the consumption 
of penicillins (−16.78%; p < 0.001), especially amoxicillin and beta-lactamase inhibitor 
(−29.42%; p < 0.001) and quinolones (−12.39%; p < 0.001). Likewise, the consumption of 
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antimycotics, expressed in DDD/100 bed-days, in 2020 also decreased with respect to 2019 
(12.35 vs. 11.81; −4.35%; p < 0.001), especially due to the decrease in the consumption of 
fluconazole (7.19 vs. 6.17; −14.12%; p < 0.001). 
On the contrary, the consumption of antibacterial use, expressed in DDD/100 dis-
charges, in 2020 increased by 23.42%, compared to 2019 (508.12 vs. 627.21; p < 0.001). This 
rise was observed in the main antibiotic families, although it has been especially important 
in macrolides (especially azithromycin 275.09%; p < 0.001), third- and fourth-generation 
cephalosporins (mainly ceftriaxone 55.11%; p < 0.001 and cefepime 106.35%; p < 0.001, re-
spectively) and the “J01X other antibacterials” group (principally vancomycin 29.81%; p < 
0.001 and linezolid 31.28%, p < 0.001). The consumption of antimycotics in 2020 per 
DDD/100 discharges increased, compared to 2019, by 19.58% (54.93 vs. 65.68; p < 0.001), 
primarily due to an increase in the consumption of amphotericin B (87.98%; p < 0.001) and 
voriconazole (96.17%, p < 0.001). 
2.5. Comparison between Estimated and Observed ICU Consumption, Expressed in DDD/100 
Discharges, in 2020 
Figure 2 shows the annual consumption in ICUs, expressed in DDD/100 discharges, 
of the different antibacterials and antimycotics for systemic use during the non-COVID-
19 period (from 2008 to 2019), as well as the consumption trend line based on these data, 
projected until 2020. 
 
Figure 2. Evolution of antibiotic and antimycotic consumption in intensive care unit (ICU) services between 2008 and 2020, 
expressed in DDD/100 discharges. Non-COVID-19 period was considered from 2008 to 2019. DDD: Defined daily doses. 
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Black circles: Antimicrobial consumption data for every year. Blue line: Antimicrobial consumption trend based on data 
from 2008 to 2019, and projected until 2020. Red triangle: Observed 2020 consumption. 
The observed consumption of antibacterials in 2020 was 627.21 DDD/100 discharges. 
This consumption is above the estimated value (545.48 DDD/100 discharges) and exceeds 
the prediction interval (PI) based on the non-COVID-19 consumption trend from 2008 to 
2019 (475.41 to 615.56 DDD/100 discharges). The 2020 consumption of antimycotics was 
65.68 DDD/100 discharges, slightly higher than the estimated value (62.78 DDD/100 dis-
charges), although within the PI (42.31 to 83.25 DDD/100 discharges). 
Observed consumptions of amphotericin B, azithromycin, caspofungin, ceftriaxone, 
vancomycin, and voriconazole were higher than estimated consumption values and 
above the calculated PI (Table 3). These data, expressed in DDD/100 bed-days, have been 
included in the Supplementary Material as Figure S1 and Table S1. 
Table 3. Comparison between expected and observed intensive care unit (ICU) consumption, expressed in DDD/100 dis-
charges. Estimated 2020 consumption was based on the trend from the non-COVID-19 period (2008–2019). 
 ICU DDD/100 Discharges 







J02AA01 Amphotericin B 1.93 3.67 90.16 [0.28 to 3.57] 
J01GB06 Amikacin 10.17 12.37 21.63 [3 to 17.34] 
J01CR02 Amoxicillin and beta-lactamase inhibitor 54.96 50.81 −7.55 [43.43 to 66.49] 
J02AX06 Anidulafungin 9.64 10.86 12.66 [6.77 to 12.52] 
J01FA10 Azithromycin 13.03 46.28 255.18 [10.66 to 15.41] 
J02AX04 Caspofungin 1.14 2.52 121.05 [0.05 to 2.23] 
J01DE01 Cefepime 7.02 11.03 57.12 [2.84 to 11.19] 
J01DD02 Ceftazidime 11.22 12.21 8.82 [7.28 to 15.16] 
J01DD04 Ceftriaxone 33.59 45.58 35.70 [25.9 to 41.29] 
J01MA02 Ciprofloxacin 14.78 19.28 30.45 [10.21 to 19.35] 
J01CF02 Cloxacillin 32.39 35.86 10.71 [27.45 to 37.33] 
J01XB01 Colistin 8.65 9.11 5.32 [0.98 to 16.32] 
J01XX09 Daptomycin 27.08 30.78 13.66 [18.92 to 35.24] 
J01DH03 Ertapenem 7.46 7.04 −5.63 [6.05 to 8.88] 
J02AC01 Fluconazole 37.17 34.34 −7.61 [20.93 to 53.4] 
J01DH51 Imipenem-cilastatin 0.0 3.89 NA [−5.22 to 5.01] 
J01XX08 Linezolid  26.73 28.12 5.20 [18.44 to 35.03] 
J01DH02 Meropenem 66.79 67.06 0.40 [51.71 to 81.87] 
J02AX05 Micafungin  4.93 2.14 −56.59 [1.28 to 8.58] 
J01CR05 Piperacillin and beta-lactamase inhibitor 46.21 53.43 15.62 [32.52 to 59.9] 
J02AC04 Posaconazole 1.17 0.51 −56.41 [−0.23 to 2.57] 
J01XA01 Vancomycin 11.32 15.97 41.08 [7.97 to 14.67] 
J02AC03 Voriconazole 6.65 9.80 47.37 [4.03 to 9.27] 
ICU: Intensive care unit; DDD: Defined daily doses. 
3. Discussion 
The effect of the COVID-19 pandemic was to produce an imbalance in the use of an-
timicrobials, probably due to an initial poor knowledge of the evolution of the disease and 
to the interruption of the regular work of PROA. 
In this study, including data from all the 66 hospitals of the VINCat program during 
the COVID-19 pandemic, antimicrobial consumption increased significantly, mainly in 
the ICU. The increase in some molecules, such as ceftazidime/avibactam, 
ceftolozane/tazobactam, colistin, amphotericin B, and voriconazole, deserves further 
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study, and the implementation of strict antibiotic policies to optimize their use is neces-
sary. Finally, when ICU data were expressed in DDD/100 bed-days compared to DDD/100 
discharges, it yielded different consumption results. 
One important finding of our study was the difference in ICU antimicrobial con-
sumption observed for some molecules depending on the denominator (bed-days or dis-
charges). The importance of describing both indicators was already described by VINCat 
in other non-COVID-19 settings, but has never been studied in COVID-19 or other pan-
demics [19]. Overall bed-days and discharges remained stable, which may explain the ab-
sence of differences when reporting consumption data. On the contrary, ICU bed-days 
increased by 29.08% and discharges by 3.24%. This may clarify the differences in some 
molecules, such as ertapenem, imipenem, or fluconazole, where DDD/100 bed-days de-
creased while DDD/100 discharges increased. The prolongation of hospital stay in ICUs 
has been essential in our results. Bearing in mind that consumption, expressed in 
DDD/100 discharges, allows us to approximate the antibiotic consumption made by each 
patient during their admission, these results indicate that, while antibiotic pressure per 
ICU day has changed relatively little (−1.28%), antibiotic pressure per ICU patient during 
the COVID-19 pandemic has increased greatly (23.42%). All these findings underline the 
importance of correlating clinical findings with consumption data, and makes difficult the 
comparison with previous non-pandemic periods. 
Concerning microbiological data, we took as a reference the National Surveillance 
Study of Nosocomial Infection in the ICU (ENVIN-HELICS) registry [20]. This study was 
conducted from March 2020 to May 2020, including 1525 patients admitted to 61 ICUs 
from 54 hospitals in Spain. This work reflects the reality of Spanish ICUs during the first 
wave of the COVID-19 pandemic and brings into question some findings observed in our 
work. 
An increase in overall antimicrobial consumption was shown, with worrisome re-
sults in ICUs. Based on Table 3, six molecules exceeded the PI: amphotericin B, caspofun-
gin, voriconazole, ceftriaxone, azithromycin, and vancomycin. 
This work is the first to report an important increase in antifungal consumption in 
ICUs. The rise in the incidence of invasive aspergillosis and candidemia during the 
COVID-19 pandemic could account for this finding [20,21]. This augmented risk is moti-
vated by the SARS-CoV-2 infection itself, the prolonged ICU stay, exposure to broad-spec-
trum antibiotics, the development of acute respiratory distress syndrome, or the use of 
immunosuppressive therapies such as corticosteroids or interleukin-6 inhibitors includ-
ing tocilizumab [21–25]. The higher risk of invasive aspergillosis may explicate the incre-
ment of voriconazole and amphotericin B consumption (which may have also been used 
as a nebulized therapy in intubated patients), although this polyene may have also been 
employed in the setting of fluconazole- and echinocandin-resistant candidiasis [25]. Echi-
nocandins could have also been used as part of a combination therapy for invasive asper-
gillosis, although the rise in candidemia essentially explains these results. The use of flu-
conazole did not rise in parallel, which may reflect the lack of antifungal de-escalation or 
a higher incidence of fluconazole-resistant strains such as Candida spp. Compared to 2019 
candidemia incidence in Spain, a higher incidence of C. albicans (7.1 vs. 5.5%) was ob-
served, whereas C. glabrata (1.47 vs. 1.57%) and C. parapsilosis (2.94 vs. 2.36%) remained 
stable [20]. Concerning fluconazole resistance, it increased compared to the previous year: 
C. albicans (2/18, 11.1% vs. 0/13, 0%), C. parapsilosis (2/6, 33.3% vs. 1/8, 12.5%). As far as 
catheter-associated urinary tract infection (CAUTI) is concerned, a higher incidence of C. 
albicans (13.2 vs. 11.2%), C. glabrata (6.4 vs. 3.3%), and C. parapsilosis (3.2 vs. 1.4%) was 
observed. Despite this increase in the incidence and resistance of candida infections, mi-
crobiology does not support a higher use of these extended spectrum molecules in Spain 
[20]. 
The management of fungal infections in ICUs is a challenge, even more so in the con-
text of COVID-19 [26]. Some PROA actions include a reduction in the length of therapy 
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when possible, dose adjustments (i.e., not exceeding the use of 3 mg/kg of liposomal am-
photericin B for invasive aspergillosis, instead of higher doses that have been proven to 
be deleterious [27]), therapeutic drug monitoring, intravenous to oral transition programs, 
or antifungal de-escalation [26]. 
Similarly, antibiotic consumption increased over this period. A higher incidence (8.1–
9.3%) of bacterial co-infection was demonstrated in critically ill patients [2,22]. Therefore, 
given the severity of patients’ health and the greater mortality found in co-infected pa-
tients, empirical antimicrobial therapy was recommended in patients admitted to ICUs 
[12]. These can justify the astonishing increment in the consumption of ceftriaxone and 
azithromycin. 
A higher consumption of drugs normally used for nosocomial infections, such as 
cefepime or meropenem, may be the consequence of a higher incidence of nosocomial 
infections [20]. As far as ventilator-associated pneumonia is concerned, Pseudomonas aeru-
ginosa was the main involved (32.5%) microorganism in Spain [20]. Compared to the pre-
vious year, the resistance profile of this microorganism did not change, with similar re-
sistance rates of meropenem, cefepime, or piperacillin/tazobactam [20]. However, a wor-
risome increase in the prevalence of carbapenem-resistant Klebsiella pneumoniae was ob-
served [20]. The increase in the consumption of amikacin and ciprofloxacin, as part of 
combination therapy recommended by guidelines, may also be related [22,28,29]. The rise 
in the consumption of these molecules probably contributed, among other factors, to a 
higher incidence of Clostridioides difficile infection, which increased from 0.14% to 0.20%. 
The rate of catheter-related bacteremia and CAUTI also increased [20]. A higher prev-
alence of enterococci (Enterococcus faecium: from 3.59% to 6.41% and Enterococcus faecalis: 
from 4.94% to 13.29%) was observed for both infections, probably due to the excessive use 
of cephalosporins [22]. The incidence of infections due to methicillin-resistant S. aureus 
also increased (from 1.35% to 1.98%). Due to these findings, the consumption of daptomy-
cin, linezolid, and vancomycin was augmented. 
A striking rise in the prescription of ceftolozane/tazobactam and ceftazidime/avibac-
tam was observed, as previously described in Spain [15]. This result deserves further 
study, but data from the ENVIN-HELICS study highlighted that colonization/infection by 
multidrug-resistant (MDR) organisms during ICU stay was more frequent during the 
COVID-19 pandemic. This finding was especially important for extended spectrum beta-
lactamases (7.5 vs. 1.8%), MDR p. aeruginosa (4.7 vs. 0.6%), and carbapenemase producing 
organisms (4.4 vs. 0.4%). 
On the other hand, the use of amoxicillin/clavulanate practically disappeared, which 
may also reflect the lack of antimicrobial de-escalation or a shift towards a greater use of 
ceftriaxone. 
Beyond microbiology, from a global perspective, several reasons may also account 
for these results. Firstly, the SARS-CoV-2 pandemic has radically changed the paradigm 
of what we have known so far about viral infections in the last 50 years. Patients with 
COVID-19 differ from those diagnosed with influenza, with an up to three-fold higher in-
hospital mortality, higher overburdened ICU capacity, ICU admission (16.3% vs. 10.8%, p 
< 0.0001), ICU mean length of stay (15 vs. 8 days, p < 0.0001), need for mechanical ventila-
tion (71.5% vs. 61.0%, p < 0.0001), and ICU mortality (27.1% vs. 18.0%, p< 0.0001) [22,30,31]. 
Secondly, other global challenges were faced: non-ICU healthcare workers not famil-
iar with infection prevention and control principles (IPCP) were admitted to ICUs, unfa-
miliarity with ICU complications, increased workload, PROA meeting suspension, use of 
unfamiliar tools and equipment, decreased attention to IPCP, shortages of personal pro-
tective equipment, and less invasive microbiological sampling due to concerns of gener-
ated aerosols [32]. 
Our study yielded important and worrisome results. The epidemic of MDR bugs is 
one of the biggest challenges of modern medicine, and the SARS-CoV-2 pandemic has 
only aggravated it [33]. In the light of further COVID-19 waves and potential pandemics 
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causes by other viruses, it is essential to learn from past mistakes and try to optimize fu-
ture processes. PROA should persist and be actively involved in the management of these 
situations [34]. To try to reduce the unnecessary antibiotic consumption in the setting of 
the COVID-19 pandemic, different strategies have been proposed, as well as recommen-
dations of research areas to strengthen PROA teams [8,32,35,36]. 
This study is not without limitations. Unfortunately, as we expressed the annual con-
sumption data, we were not able to discern the impacts of the different waves (and, there-
fore, variants). Likewise, we did not study the indications of the antimicrobials, nor their 
duration, if they were empirical or directed, and the isolated microbiology. The lack of 
microbiological data is an important limitation to study the potential justification of pre-
scribed antibiotics. In addition, the lack of this information together with the observational 
nature of the study precludes the demonstration of a temporary association between an-
tibiotic exposure and resistance. We acknowledge that an analysis of the impact of the 
different types of hospitals would have been of interest, but this was out of our scope. 
Finally, we recognize that the use of DDD may not be the best indicator in an ICU setting, 
where higher or reduced doses can be employed compared to pre-defined standard doses 
[37]. This finding may be more evident during the COVID-19 pandemic, where a higher 
prevalence of obesity or need for mechanical ventilation and renal replacement therapies 
was observed [31,32]. Although days of therapy is the recommended indicator by the 
WHO, they are not always available. 
4. Materials and Methods 
4.1. Setting and Study Design 
All acute care hospitals affiliated with the VINCat program [16] participated in this 
retrospective, longitudinal, and descriptive study. 
4.2. Data Collection 
The anatomical therapeutic chemical/DDD (ATC/DDD), system developed and up-
dated by the World Health Organization (WHO) Collaborating Centre for Drug Statistics 
Methodology has become an international standard for drug metrics and facilitates the 
presentation and comparison of drug consumption statistics at international, national, and 
regional levels. In 2008, the VINCat-PROA adopted the ATC/DDD system as a standard-
ized measure. 
The ATC/DDD system was used to monitor adult hospital anti-infectives for systemic 
use consumption every year. The pharmacy departments at the participating hospitals 
reported the number of units of each antibacterial for systemic use (J01) and antimycotic 
for systemic use (J02) dispensed from the whole hospital, from the medical and surgical 
units, and from the ICUs. Bed-days data and discharge data were also informed. The ad-
mission and discharge days were considered as a single day [19]. 
Adult antibacterial and antimycotic consumption were calculated for each year as 
DDD/100 bed-days and DDD/100 discharges with the WHO ATC/DDD index 2021. 
All hospitals received appropriate training before starting the study and on an annual 
basis by the VINCat coordinating center, to guarantee an homogeneous collection of the 
data according to pre-established criteria [16]. Afterwards, all the registered information 
was assessed and validated. 
4.3. Statistical Analysis 
Differences in antibacterial and antimycotic consumption, expressed in DDD/100 
bed-days and DDD/100 discharges, between 2019 and 2020 were analyzed using the exact 
rate ratio test, achieving their corresponding confidence intervals (CIs) and p-values for 
each comparison. 
Estimated non-COVID-19 2020 antibiotic and antimycotic ICU consumption was es-
timated by a simple linear regression model, considering only the period 2008–2019 in the 
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predictor variable. Observed ICU 2020 consumptions were compared with non-COVID-
19 2020 estimated ICU consumptions, and the corresponding PI were obtained to compare 
them with their respective observed 2020 ICU consumptions. 
For all statistical analysis, 95% CIs and PIs were calculated. p-values of <0.05 were 
considered statistically significant. A bilateral distribution was assumed for all p-values. 
The analyses were performed using R v4.0.4 statistical software. 
5. Conclusions 
In summary, the consumption indicators for most antimicrobials have deviated from 
the expected trend pattern based on the information available from previous years. The 
greater increase in DDD/100 discharges reflects a higher individual exposure to antimi-
crobials, with the consequent risk of altering the microbiota of patients admitted to VIN-
Cat hospitals during the COVID-19 pandemic. Future studies should assess the real im-
pact of these findings. 
Supplementary Materials: The following are available online at www.mdpi.com/article/10.3390/an-
tibiotics10080943/s1. Figure S1: Evolution of antibiotic and antimycotic consumption in ICU services 
between 2008 and 2020, expressed in DDD/100 bed-days. Non-COVID-19 period was considered 
from 2008 to 2019. Table S1: Comparison between expected and observed intensive care unit (ICU) 
consumption, expressed in DDD/100 bed-days. Estimated 2020 consumption was based on the trend 
from the non-COVID-19 period (2008–2019). 
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